福泰制药
VRTX463.070USD
+6.200+1.36%
交易中 （美东）报价延迟15分钟
118.99B总市值
亏损市盈率 TTM
关于 Vertex Pharmaceuticals Inc 公司
Vertex Pharmaceuticals Incorporated 是一家全球性生物技术公司。该公司专注于投资科学创新，为患有严重疾病的人创造变革性药物，重点关注专业市场。该公司拥有四种获批的治疗囊性纤维化 (CF) 潜在病因的药物，以及一种获批的治疗严重镰状细胞病 (SCD) 和输血依赖性β地中海贫血 (TDT) 的疗法。其产品线包括 CF、SCD、TDT、急性和神经性疼痛、APOL1 介导的肾脏疾病、1 型糖尿病、1 型肌强直性营养不良和 α-1 抗胰蛋白酶缺乏症的临床阶段项目。其上市药物包括 TRIKAFTA/KAFTRIO、SYMDEKO/SYMKEVI（tezacaftor/ivacaftor 和 ivacaftor）、ORKAMBI（lumacaftor/ivacaftor）和 KALYDECO（ivacaftor）。该公司正在开发非自体（同种异体）完全分化、干细胞衍生的胰岛细胞疗法，旨在取代 1 型糖尿病患者体内被破坏的产生胰岛素的胰岛细胞。
公司简介
公司代码VRTX
公司名称Vertex Pharmaceuticals Inc
上市日期Jul 24, 1991
成立日期1989
CEODr. Reshma Kewalramani
员工数量6100
证券类型Ordinary Share
年结日Jul 24
公司地址50 Northern Avenue
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02210
电话16173416393
网址https://www.vrtx.com/
公司代码VRTX
上市日期Jul 24, 1991
成立日期1989
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.83K
+8.93%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
地区USD
名称
营收
占比
United States
1.65B
59.91%
Europe
826.60M
29.95%
Other
280.10M
10.15%
业务
地区
业务USD
名称
营收
占比
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
股东统计
更新时间: 5月15日 周四
更新时间: 5月15日 周四
持股股东
股东类型
持股股东
持股股东
占比
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
持股股东
持股股东
占比
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
股东类型
持股股东
占比
Investment Advisor
59.70%
Investment Advisor/Hedge Fund
28.09%
Research Firm
2.55%
Pension Fund
2.36%
Bank and Trust
2.04%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.29%
Insurance Company
0.16%
Individual Investor
0.14%
Other
2.22%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
2926
251.46M
97.92%
+1.75M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
28.53M
11.11%
+207.61K
+0.73%
Mar 31, 2025
The Vanguard Group, Inc.
23.38M
9.1%
+232.41K
+1.00%
Mar 31, 2025
Capital Research Global Investors
14.54M
5.66%
+4.11M
+39.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.00M
5.45%
-330.35K
-2.31%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.59%
-190.75K
-1.59%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
2.97%
-1.49M
-16.32%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.76M
2.24%
+113.52K
+2.01%
Mar 31, 2025
Wellington Management Company, LLP
5.45M
2.12%
-461.34K
-7.80%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
5.31M
2.07%
-20.76K
-0.39%
Jun 30, 2025
JP Morgan Asset Management
5.18M
2.02%
+557.84K
+12.08%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
VanEck Biotech ETF
11.07%
Tema Neuroscience and Mental Health ETF
9.96%
Invesco Nasdaq Biotechnology ETF
8.3%
ProShares Ultra Nasdaq Biotechnology
7.94%
iShares Biotechnology ETF
7.48%
Natixis Loomis Sayles Focused Growth ETF
5.26%
Franklin Genomic Advancements ETF
5.01%
Global X Genomics & Biotechnology ETF
3.83%
Tema Heart & Health ETF
3.02%
First Trust NYSE Arca Biotechnology Index Fund
2.87%
查看更多
VanEck Biotech ETF
占比11.07%
Tema Neuroscience and Mental Health ETF
占比9.96%
Invesco Nasdaq Biotechnology ETF
占比8.3%
ProShares Ultra Nasdaq Biotechnology
占比7.94%
iShares Biotechnology ETF
占比7.48%
Natixis Loomis Sayles Focused Growth ETF
占比5.26%
Franklin Genomic Advancements ETF
占比5.01%
Global X Genomics & Biotechnology ETF
占比3.83%
Tema Heart & Health ETF
占比3.02%
First Trust NYSE Arca Biotechnology Index Fund
占比2.87%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
